Yes, Sodium Zirconium Cyclosilicate is Lokelma
Sodium zirconium cyclosilicate (SZC) is the active pharmaceutical ingredient in Lokelma, a non-absorbed potassium binder approved for treating hyperkalemia in adults. 1
Mechanism and Formulation
Lokelma is a white to grey powder for oral suspension that works by preferentially exchanging potassium for hydrogen and sodium in the gastrointestinal tract, thereby increasing fecal potassium excretion and lowering serum potassium levels. 1 The medication is not systemically absorbed and acts entirely within the GI lumen. 1
Important sodium content: Each 5 g dose contains 400 mg of sodium, which is clinically relevant for patients with heart failure or volume-sensitive conditions. 1
Indications
Lokelma is indicated for the treatment of hyperkalemia in adults. 1 Current guidelines strongly support its use in two clinical scenarios:
- Acute hyperkalemia management: Can be used alongside conventional treatments (calcium, insulin/dextrose, salbutamol) for rapid potassium reduction 2, 3
- Chronic/recurrent hyperkalemia: Particularly valuable for enabling continuation of life-saving RAAS inhibitor therapy in patients with heart failure, CKD, or diabetes 2
The 2025 European guidelines emphasize that potassium binders like SZC should be initiated when there is no acute reversible factor and the patient is at risk for recurrent hyperkalemia, rather than discontinuing disease-modifying RAAS inhibitor therapy. 2
Dosing Regimens
Correction Phase (Acute Treatment)
Standard dosing: 10 g three times daily for up to 48 hours 1, 4, 5
- Potassium reduction begins within 1 hour of first dose 1
- Mean reduction of approximately 1.28 mmol/L at 48 hours 5
- 92.9% of patients achieve normokalaemia (3.5-5.0 mmol/L) within 48 hours 5
Maintenance Phase (Chronic Management)
After achieving normokalaemia, transition to 5 g or 10 g once daily 1, 5
- Dose titration based on serum potassium monitoring
- Most patients maintained on <15 g once daily in long-term studies 1
- Can be used for up to 12 months with consistent safety profile 6
Special Populations
Hemodialysis patients: Administer on non-dialysis days only, with dose adjustment based on pre-dialysis potassium after the long inter-dialytic interval 7
Drug interactions: Administer other oral medications at least 2 hours before or after Lokelma, as it transiently increases gastric pH and may affect absorption of pH-dependent drugs 1
Key Safety Considerations
Monitor for edema: Dose-dependent edema occurs in 4.4% (5 g), 5.9% (10 g), and 16.1% (15 g) of patients versus 2.4% with placebo 1. This is particularly important in heart failure patients given the sodium content.
Hypokalemia risk is low but real: 4.1% of non-dialysis patients develop potassium <3.5 mmol/L, which resolves with dose reduction 1. No severe hypokalemia (<3.0 mmol/L) was observed in most studies 7.
Constipation: Mild to moderate constipation is the most common adverse effect 5, 8
Clinical Advantages Over Alternatives
Recent meta-analysis demonstrates that SZC provides faster potassium reduction than patiromer during the initial 48-72 hours (WMD -0.45 mEq/L), making it superior for acute management 8. Both agents are effective for maintenance, but SZC has higher rates of normokalaemia achievement (77.3% vs 58.6% at lower doses) 5.
The critical clinical benefit is enabling RAAS inhibitor optimization—up to one-third of heart failure patients develop hyperkalemia on MRAs, and SZC allows continuation of these life-saving medications rather than dose reduction or discontinuation. 2, 3